Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
TEPEZZA Data Published Twice in The New England Journal of Medicine
One of Few Clinical Programs to Have Both Phase 2 and Phase 3 Clinical Results Featured in the Journal
Phase 2 Results: May 2017
The NEW ENGLAND JOURNAL of MEDICINE
ORIGINAL ARTICLE
Phase 3 Results: January 2020
The NEW ENGLAND JOURNAL of MEDICINE
ORIGINAL ARTICLE
HORIZON
Teprotumumab for Thyroid-Associated
Ophthalmopathy
Terry J. Smith, M.D., George J. Kahaly, M.D., Ph.D., Daniel G. Ezra, M.D.,
James C. Fleming, M.D., Roger A. Dailey, M.D., Rosa A. Tang, M.D.,
Gerald J. Harris, M.D., Alessandro Antonelli, M.D., Mario Salvi, M.D.,
Robert A. Goldberg, M.D., James W. Gigantelli, M.D., Steven M. Couch, M.D.,
Erin M. Shriver, M.D., Brent R. Hayek, M.D., Eric M. Hink, M.D.,
Richard M. Woodward, Ph.D., Kathleen Gabriel, R.N., Guido Magni, M.D., Ph.D.,
and Raymond S. Douglas, M.D., Ph.D.
"In conclusion, a 24-week course of teprotumumab therapy
provided clinical benefit in patients with active, moderate-
to-severe thyroid-associated ophthalmopathy by reducing
proptosis and the Clinical Activity Score and by improving
the patients' quality of life." (2)
(1) Douglas Raymond S, The New England Journal of Medicine; 382 January 23, 2020, p341-352.
(2) Smith Terry J, Hegedus Laszlo., Graves' disease, The New England Journal of Medicine; 375 July 3, 2016, p. 1552-1565.
Teprotumumab for the Treatment
of Active Thyroid Eye Disease
R.S. Douglas, G.J. Kahaly, A. Patel, S. Sile, E.H.Z. Thompson, R. Perdok,
J.C. Fleming, B.T. Fowler, C. Marcocci, M. Marinò, A. Antonelli, R. Dailey,
G.J. Harris, A. Eckstein, J. Schiffman, R. Tang, C. Nelson, M. Salvi,
S. Wester, J.W. Sherman, T. Vescio, R.J. Holt, and T.J. Smith
"Among patients with active thyroid eye disease,
teprotumumab resulted in better outcomes with respect to
proptosis, Clinical Activity Score, diplopia, and quality of life
than placebo; serious adverse events were uncommon." (1)
Clinical Activity Score (CAS): a 7-point scale that measures change in orbital inflammation and pain; a score of >3 indicates active TED.
17View entire presentation